At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELVN Enliven Treateutics
Trading 07-02 14:35:45 EDT
50.02
+1.26
+2.58%
High50.21Low47.45Vol522.58K
Open48.76D1 Closing48.76Amplitude5.66%
Mkt Cap3.57BTradable Cap2.76BTotal Shares71.44M
T/O25.79MT/O Rate0.95%Tradable Shares55.26M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Orbimed Advisors Reports Enliven Therapeutics Common Stock Sale Worth $38.02 Million
Reuters  ·  06-25
Orbimed Advisors Reports Enliven Therapeutics Common Stock Sale Worth $38.02 Million
Enliven Therapeutics CMO Helen Louise Collins disposes of USD 217,816 in common shares
Reuters  ·  06-23
Enliven Therapeutics CMO Helen Louise Collins disposes of USD 217,816 in common shares
OrbiMed Advisors reports $12.67 million Enliven Therapeutics common stock sale
Reuters  ·  06-18
OrbiMed Advisors reports $12.67 million Enliven Therapeutics common stock sale
Enliven Therapeutics Closes Upsized $460 Million Public Offering
MT Newswires Live  ·  06-16
Enliven Therapeutics Closes Upsized $460 Million Public Offering
Enliven Therapeutics closes upsized public offering, raises USD 460 million gross
Reuters  ·  06-16
Enliven Therapeutics closes upsized public offering, raises USD 460 million gross
Jefferies Remains a Buy on Enliven Therapeutics (ELVN)
TIPRANKS  ·  06-15
Jefferies Remains a Buy on Enliven Therapeutics (ELVN)
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Twist Bioscience (TWST)
TIPRANKS  ·  06-15
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Twist Bioscience (TWST)
Why Is Enliven Therapeutics Stock (ELVN) Up Today?
TIPRANKS  ·  06-13
Why Is Enliven Therapeutics Stock (ELVN) Up Today?
Enliven rises 9.9%
TIPRANKS  ·  06-13
Enliven rises 9.9%
BUZZ-Enliven soars after boosted equity raise for leukemia drug
Reuters  ·  06-12
BUZZ-Enliven soars after boosted equity raise for leukemia drug
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut
MT Newswires Live  ·  06-12
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut
Enliven Therapeutics Prices $400 Million Public Offering
MT Newswires Live  ·  06-12
Enliven Therapeutics Prices $400 Million Public Offering
BRIEF-Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per Share
Reuters  ·  06-12
BRIEF-Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per Share
Enliven Therapeutics prices upsized public offering at $37.5 per share, targets $400 million gross proceeds
Reuters  ·  06-12
Enliven Therapeutics prices upsized public offering at $37.5 per share, targets $400 million gross proceeds
Enliven: Prices 8.9 Mln Shares at $37.50 per Share
THOMSON REUTERS  ·  06-12
Enliven: Prices 8.9 Mln Shares at $37.50 per Share
BRIEF-Enliven Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Reuters  ·  06-12
BRIEF-Enliven Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Enliven Therapeutics launches USD 250 million stock, pre-funded warrant offering
Reuters  ·  06-12
Enliven Therapeutics launches USD 250 million stock, pre-funded warrant offering
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
THOMSON REUTERS  ·  06-12
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Boris Peaker Reiterates Buy Rating and $45 Price Target on ELVN-001 After Strong Phase 1b CML Data Support Best-in-Class Potential
TIPRANKS  ·  06-11
Boris Peaker Reiterates Buy Rating and $45 Price Target on ELVN-001 After Strong Phase 1b CML Data Support Best-in-Class Potential
Enliven rises 14.8%
TIPRANKS  ·  06-11
Enliven rises 14.8%

Introduction

Company Name.
Enliven Treateutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
Issue price:
--